Stay updated with breaking news from Therapeutic Development Programs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE:NAVB opened at $0.07 on Tuesday. Navidea Biopharmaceuticals has a one year low of $0.07 and a one year high of $0.62. […]
A number of research firms have changed their ratings and price targets for Navidea Biopharmaceuticals (NYSE: NAVB): 7/8/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 6/30/2023 – Navidea Biopharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a drop of 35.3% from the May 31st total of 881,100 shares. Currently, 4.5% of the company’s shares are short sold. Based […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily trading volume, of 5,430,000 shares, the short-interest ratio […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily volume of 5,430,000 shares, the […]